iPS Cells & Regenerative Medicine Weekly Report May 13, 2026

Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges

CombiCult® Screening Platform Establishes Feeder-Free Bioreactor Scalability for iPSC-Derived NK Cell Manufacturing

REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies

Human Continuum Closes Over $5 Million in Seed Round Funding to Advance Exosome-Based Therapeutic Longevity Platform Development

Novartis and Orionis Biosciences Enter Strategic Collaboration for Molecular Glue Discovery in Up to $1.4 Billion Deal

AmMax Bio Licenses Lonza’s Conjugation and Linker-Payload Technologies for ADC Program AMB-104

Cartesian Therapeutics and WestGene Biopharma Announce Strategic Licensing Agreement to Accelerate In Vivo CAR T Platform Development for Autoimmune Diseases

ENCell Secures US Clinical Manufacturing Contract for Ingenium Therapeutics’ NK Cell Therapy Gengleucel, Expanding Global CDMO Operations